Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2023-05-11 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2023-05-11 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma has received Health Canada authorization to proceed with a Phase 1 clinical trial for its new drug ARDS-003. It discusses the drug candidate, the clinical trial phase, funding support, and forward-looking statements. There are no financial statements, earnings data, or detailed financial analysis. The content is an update on a clinical trial authorization, which is a capital/financing or operational update related to the company's drug development progress. It is not an annual report, earnings release, or regulatory filing of financial results. The best fitting category is Capital/Financing Update (CAP) as it relates to the company's progress in drug development and funding support for the clinical trial.
2023-03-10 English
News release - English.pdf
Regulatory Filings
2023-03-07 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma has received government funding to support the development of a drug candidate (ARDS-003). It discusses the funding amount, the purpose of the funding, and some background on the drug and company. There are no financial statements, no detailed financial performance data, no regulatory filings, no management or board changes, no voting results, no earnings data, and no detailed investor presentation content. The document is primarily an update on financing support from a government program for R&D purposes. This fits best under Capital/Financing Update (CAP) as it relates to funding received by the company to support its development activities. The document length is 6578 characters, which is sufficient for a substantive announcement but does not contain financial report data. Therefore, the classification is CAP with high confidence.
2023-03-03 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a delay in filing the company's 2022 annual financial statements and related management's discussion and analysis. It mentions the resignation of auditors and the application for a management cease trade order due to the delay. The document does not contain the actual financial statements or detailed management discussion and analysis, but rather informs about the delay and regulatory steps taken. It is an announcement related to regulatory compliance and filing status, not the actual annual report or financial statements. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement about filing delays and related regulatory actions.
2023-03-01 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma Inc. has begun trading its common shares on the OTC Pink Market in the United States. It provides details about the listing, the market, and the company's business focus. There is no financial data, no report attached or referenced as being published, no management discussion or detailed financial results, and no regulatory certification. The document is an announcement about a capital market listing event, specifically a listing to a new trading market. This fits best under Capital/Financing Update (CAP) as it relates to changes in the company's capital market presence and trading venues.
2023-02-11 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.